Abstract: Presentation of membrane proteins to host immune systems has been a challenging problem due to complexity arising from the poor in vivo stability of the membrane-mimetic media often used for solubilizing the membrane proteins. The Inventors report the use of functionalized, biocompatible nanoparticles as substrates to guide the formation of proteoliposomes that can present many copies of membrane proteins in a unidirectional manner. The approach was demonstrated to present the membrane-proximal region of the HIV-1 envelope glycoprotein. These nanoparticle-supported liposomes are broadly applicable as membrane antigen vehicles for inducing host immune responses. In some instances, the technology supports generation of antibodies that do not generate an immunogenic response in comparison to conventional protein presentation (i.e., liposome).

Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.

Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.

Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of cancer.

Abstract: The present invention relates to histone deacetylase inhibitors, and to pharmaceutical compositions comprising the compounds, useful for the treatment of ischemia-reperfusion injury and for cardioprotection.

Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of cancer.

Abstract: The present invention relates to histone deacetylase inhibitors, and to pharmaceutical compositions comprising the compounds, useful for the treatment of ischemia-reperfusion injury and for cardioprotection.

Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.

Abstract: The invention provides methods of treating Friedreich's ataxia and other neurodegenerative or neuromuscular conditions using histone deacetylase inhibitors.

Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

Abstract: Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.

Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.

Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.

Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.

Abstract: The present invention generally relates to influenza and, in particular, to systems and methods for studying influenza viruses such as the influenza A virus. One aspect of the invention is generally directed towards systems and methods for determining the timescale dynamics of the tryptophan residue located in position 41 of the M2 proton channel of the influenza A virus, for instance, via nuclear magnetic resonance. This may be useful, for example, in determining whether a candidate drug is able to alter the dynamics of the tryptophan residue, and thus, whether the drug targets the M2 proton channel.

Abstract: A communication provider which provides wireless access to a packetized data network, such as the Internet. The provider includes a server computer. The server computer is connected to the network, which is at least in part a wired network. A client device is also connected to the network, including by wireless means. The wired network is connected to a cellular wireless communications system. Payloads of information communicated by the server computer to the client device are assigned corresponding Global Sequence Numbers. By determining a time differential between next succeeding payloads received by the client, a determination is made whether any payload loss occurs on a wired portion of the network or on a wireless portion of the network. Headers of all payloads of information are compressed together and transmitted together, in order to limit communications and amount of data communicated. A send rate of the server computer is adjusted in relation to an effective receive rate of the client device.

Abstract: An overload prevention plug structure has a power line, a plug and an overload shift. The power line has a hot wire and a ground wire. The plug has a hot wire pin and a ground wire pin. The ground wire pin is electrically connected to the ground wire of the power line. The overload shift has a hot wire contacting portion and a pin contacting portion. The hot wire contacting portion is electrically connected to the hot wire of the power line and the pin contacting portion is electrically connected to the hot wire pin of the plug to establish an electric connection. The overload has a dual metal piece that deforms and bends as its temperature increases. Alternatively, the overload is a positive temperature coefficient (PTC) thermstor with a resistance that increases or decreases as its temperature increases or decreases.